Search Results - "Herbst, Roy"

The biology and management of non-small cell lung cancer by Herbst, Roy S., Morgensztern, Daniel, Boshoff, Chris

“…Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the…”
Get full text

Toward personalized treatment approaches for non-small-cell lung cancer by Wang, Meina, Herbst, Roy S., Boshoff, Chris

“…Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer…”
Get full text

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC by Grant, Michael J., Herbst, Roy S., Goldberg, Sarah B.

“…The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly evolving. Immune-checkpoint inhibitors, specifically those targeting…”
Get full text

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities by Kim, Tae Kon, Vandsemb, Esten N., Herbst, Roy S., Chen, Lieping

“…Tumours employ various tactics to adapt and eventually resist immune attack. These mechanisms are collectively called adaptive immune resistance (AIR). The…”
Get full text

Lung cancer in the era of precision medicine by Politi, Katerina, Herbst, Roy S

“…The past decade has been transformative for lung cancer patients, physicians, and scientists. The discovery of EGFR mutations that confer sensitivity to…”
Get full text

Defining and Understanding Adaptive Resistance in Cancer Immunotherapy by Kim, Tae Kon, Herbst, Roy S., Chen, Lieping

“…Despite the unprecedented tumor regression and long-term survival benefit observed with anti-programmed death (PD) [anti-PD-1 or anti-B7-homolog 1 (B7-H1)]…”
Get full text

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes by Doroshow, Deborah B, Sanmamed, Miguel F, Hastings, Katherine, Politi, Katerina, Rimm, David L, Chen, Lieping, Melero, Ignacio, Schalper, Kurt A, Herbst, Roy S

“…Immune-checkpoint inhibitors (ICI), particularly inhibitors of the PD-1 axis, have altered the management of non-small cell lung cancer (NSCLC) over the last…”
Get full text

ASCO 2023: Targeted Therapy for Early-Stage NSCLC by Roy Herbst

Get full text

Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling by Zugazagoitia, Jon, Gupta, Swati, Liu, Yuting, Fuhrman, Kit, Gettinger, Scott, Herbst, Roy S, Schalper, Kurt A, Rimm, David L

“…Only a minority of patients with advanced non-small cell lung cancer (NSCLC) truly benefits from single-agent PD-1 checkpoint blockade, and more robust…”
Get full text

When immunotherapy meets surgery in non-small cell lung cancer by Herbst, Roy S., Wang, Meina, Chen, Lieping

“…The results of the most recent Checkmate-816 trial in The New England Journal of Medicine using combination neoadjuvant immunotherapy with platinum-based…”
Get full text

Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer by Morgensztern, Daniel, Herbst, Roy S

“…The outcomes for patients with previously treated advanced stage non-small lung cancer (NSCLC) are very poor, with a modest benefit from chemotherapy over best…”
Get full text

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy by Liu, Yuting, Zugazagoitia, Jon, Ahmed, Fahad Shabbir, Henick, Brian S, Gettinger, Scott N, Herbst, Roy S, Schalper, Kurt A, Rimm, David L

“…Programmed death ligand 1 (PD-L1) is expressed in tumor cells and immune cells, and both have been associated with response to anti-PD-1 axis immunotherapy…”
Get full text

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial by Goldberg, Sarah B, Dr, Gettinger, Scott N, MD, Mahajan, Amit, MD, Chiang, Anne C, MD, Herbst, Roy S, Prof, Sznol, Mario, Prof, Tsiouris, Apostolos John, MD, Cohen, Justine, DO, Vortmeyer, Alexander, MD, Jilaveanu, Lucia, MD, Yu, James, MD, Hegde, Upendra, MD, Speaker, Stephanie, BA, Madura, Matthew, BS, Ralabate, Amanda, BSN, Rivera, Angel, MS, Rowen, Elin, MSN, Gerrish, Heather, BSN, Yao, Xiaopan, PhD, Chiang, Veronica, MD, Kluger, Harriet M, Prof

“…Summary Background Immunotherapy targeting the PD-1 axis has activity in several tumour types. We aimed to establish the activity and safety of the PD-1…”
Get full text

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial by Herbst, Roy S, Prof, Baas, Paul, Prof, Kim, Dong-Wan, MD, Felip, Enriqueta, MD, Pérez-Gracia, José L, MD, Han, Ji-Youn, Prof, Molina, Julian, MD, Kim, Joo-Hang, Prof, Arvis, Catherine Dubos, MD, Ahn, Myung-Ju, Prof, Majem, Margarita, MD, Fidler, Mary J, MD, de Castro, Gilberto, MD, Garrido, Marcelo, MD, Lubiniecki, Gregory M, MD, Shentu, Yue, PhD, Im, Ellie, MD, Dolled-Filhart, Marisa, PhD, Garon, Edward B, MD

“…Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for…”
Get full text

Tumor infiltrating lymphocytes - location for prognostic evaluation by Peled, Michael, Onn, Amir, Herbst, Roy S

“…Tumor infiltrating lymphocytes (TIL) are crucial for the success of immunotherapy and their density can predict prognosis. It has now been shown that…”
Get full text

To kill a tumor cell: the potential of proapoptotic receptor agonists by Ashkenazi, Avi, Herbst, Roy S

“…Disturbances in mechanisms that direct abnormal cells to undergo apoptosis frequently and critically contribute to tumorigenesis, yielding a logical target for…”
Get full text

'Undruggable' cancer protein targeted by Herbst, Roy S, Schlessinger, Joseph

“…The authors showed that AMG 510 inhibits the exchange of GDP for GTP more potently than does ARS-1620. [...]AMG 510 strongly inhibits phosphorylation of the…”
Get full text

Small molecule combats cancer-causing KRAS protein at last by Herbst, Roy S., Schlessinger, Joseph

“…A molecule has now been characterized that acts to inhibit a cancer-causing form of KRAS protein and stimulate the immune system. The inhibitor is one of the…”
Get full text

Objective measurement and clinical significance of TILs in non-small cell lung cancer by Schalper, Kurt A, Brown, Jason, Carvajal-Hausdorf, Daniel, McLaughlin, Joseph, Velcheti, Vamsidhar, Syrigos, Konstantinos N, Herbst, Roy S, Rimm, David L

“…Tumor-infiltrating lymphocytes (TILs) are usually measured using subjective methods. Studies suggest that TIL subtypes have independent roles in cancer and…”
Get full text

Review of epidermal growth factor receptor biology by Herbst, Roy S

“…The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that constitutes one of four members of the erbB family of tyrosine kinase…”
Get more information